InvestSMART

AFT Pharmaceuticals Limited (ASX:AFP)

ALERT: Price-sensitive ASX Announcement for AFP
Current share price for AFP : $3.040 0.33 (12.18%)+
Announcement
Release
20 Nov 2025 7:31AM
Price at Release
$2.710
Full Release
download
Summary
AFT Pharmaceuticals Limited reported a robust financial performance for the first half of FY26, ending 30 September 2025, achieving a 33% increase in revenue to $114.9 million. The growth was primarily driven by strong sales in Australia and recovery in Asian and International markets. The company achieved an operating profit of $4.7 million and a net profit after tax of $2.7 million. AFT continued its investment in R&D and international expansion, focusing on its innovative portfolio. The company executed multiple out-licensing agreements and advanced its in-licensing program to enhance its product offerings. It anticipates greater second-half sales, aiming to meet its FY26 operating profit guidance of $20-24 million and achieving a revenue target of $300 million by FY27.
Key Points
  • Revenue grew by 33% to $114.9 million.
  • Strong growth observed in Australian, Asian, and International markets.
  • Operating profit reached $4.7 million.
  • Net profit after tax was $2.7 million.
  • Continued investment in international business hubs and R&D.
  • Executed multiple out-licensing agreements.
  • Advanced in-licensing program to enhance product offerings.
  • Anticipates stronger sales in the second half of FY26.
  • Targets $300 million in revenue by FY27.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.